Aller au contenu principal
Profil bibliographique

Azad Kala Bhushan

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

13Publications signalées
2287Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19Respiratory Support and MechanismsAdrenal Hormones and Disorders

Les publications récentes

Accès ouvert 2026 article OpenAlex

Styloidogenic Internal Carotid Artery Dissection Presenting as Severe New-Onset Headache in a Young Adult

Azad Kala Bhushan, John Omomila, Catherine E Harris, Jane Sword

Cervical artery dissection is a leading cause of stroke in young adults and may present with isolated headache without objective focal neurological deficit. Vascular Eagle syndrome (also known as stylocarotid artery syndrome) is a specific variant of Eagle syndrome, characterised by an …

gb (code pays fourni par la source)

0 citations Cureus
2026 article OpenAlex

Organising pneumonia in ulcerative colitis with primary sclerosing cholangitis: drug-related toxicity or extraintestinal manifestation?

Fakhirah Badrulhisham, Azad Kala Bhushan, Yousra Djouider, Jonathan Digby-Bell

Pulmonary manifestations of inflammatory bowel disease (IBD) are rare but clinically significant. We present a case of a man in his 20s with ulcerative colitis and primary sclerosing cholangitis (PSC), who developed exertional breathlessness, cough and systemic symptoms. Imaging revealed bilateral pulmonary …

be, gb (code pays fourni par la source)

0 citations BMJ Case Reports
Accès ouvert 2025 article OpenAlex

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas, Kaja Abbas et autres

BACKGROUND: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital …

0 citations The Lancet Infectious Diseases
Accès ouvert 2025 article OpenAlex

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas, Jonathan R. Abbas et autres

BACKGROUND: Molnupiravir and nirmatrelvir-ritonavir are oral antivirals that have shown efficacy in preventing disease progression in outpatients with COVID-19. We aimed to evaluate these treatments for patients hospitalised with COVID-19 pneumonia, for whom data on these antivirals are scarce. METHODS: The RECOVERY …

11 citations The Lancet Infectious Diseases
Accès ouvert 2025 article OpenAlex

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas, Jaffar Abbas et autres

Background: Low dose corticosteroids (e.g., 6 mg dexamethasone) have been shown to reduce mortality for hypoxic COVID-19 patients. We have previously reported that higher dose corticosteroids cause harm in patients with clinical hypoxia but not receiving ventilatory support (the combination of non-invasive …

3 citations EClinicalMedicine
Accès ouvert 2023 article OpenAlex

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas, Jonathan R. Abbas et autres

BACKGROUND: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19. METHODS: In the randomised, controlled, …

41 citations The Lancet Diabetes & Endocrinology
2023 conference-paper OpenAlex

P6 Nutritional assessment of patients with cirrhosis is suboptimal: results of the evaluation of NutRition in CirrHosis (ENRICH) study

Keith Pohl, Kushala Abeysekera, Katherine Belfield, Simeng Lin et autres

Introduction Oral nutritional supplementation in hospitalised patients with cirrhosis reduces mortality and re-admission. All inpatients with cirrhosis should receive formal assessment by a dietician within 24 hours. ENRICH is a regional service evaluation of nutritional services provided to inpatients with cirrhosis in …

us, gb (code pays fourni par la source)

0 citations Poster presentations
Accès ouvert 2023 article OpenAlex

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, Joshua Abbas et autres

BACKGROUND: Low-dose corticosteroids have been shown to reduce mortality for patients with COVID-19 requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation). We evaluated the use of a higher dose of corticosteroids in this patient group. …

gb (code pays fourni par la source)

132 citations The Lancet
Accès ouvert 2022 article OpenAlex

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Obbina Abani, Ali Abbas, Fatima Abbas, Joshua Abbas et autres

BACKGROUND: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1-2 inhibitor, for the treatment of patients admitted to hospital with COVID-19. METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible …

gb (code pays fourni par la source)

335 citations The Lancet
Accès ouvert 2022 article OpenAlex

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, Mustafa Abbas et autres

BACKGROUND: Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab …

384 citations The Lancet
Accès ouvert 2021 article OpenAlex

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, Mustafa Abbas et autres

BACKGROUND: Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients admitted to hospital with COVID-19. METHODS: In this randomised, controlled, open-label, platform trial, …

gb, id, np, vn (code pays fourni par la source)

292 citations The Lancet
Accès ouvert 2021 article OpenAlex

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, Mustafa Abbas et autres

BACKGROUND: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of …

gb, au (code pays fourni par la source)

524 citations The Lancet

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.